Emerging evidence from various research groups suggests a positive association between IDH mutation status and improved clinical outcomes, particularly in terms of extended overall survival rates, for grade 4 astrocytoma patients [54,56,57,58]. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).